Prevalence and Genetics of Leber Hereditary Optic Neuropathy in the Danish Population by Rosenberg, Niels Thomas et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Prevalence and Genetics of Leber Hereditary Optic Neuropathy in the Danish
Population
Rosenberg, Niels Thomas; Nørby, Søren; Schwartz, Marianne; Saillard, Juliette; Magalhães,
Paulo J; Leroy, David; Kann, Erik C; Duno, Morten
Published in:






Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Rosenberg, N. T., Nørby, S., Schwartz, M., Saillard, J., Magalhães, P. J., Leroy, D., ... Duno, M. (2016).
Prevalence and Genetics of Leber Hereditary Optic Neuropathy in the Danish Population. Investigative
Ophthalmology & Visual Science, 57(3), 1370-1375. https://doi.org/10.1167/iovs.15-18306
Download date: 03. Feb. 2020
Genetics
Prevalence and Genetics of Leber Hereditary Optic
Neuropathy in the Danish Population
Thomas Rosenberg,1,2 Søren Nørby,2 Marianne Schwartz,3 Juliette Saillard,4 Paulo J. Magalha˜es,5
David Leroy,6 Erik C. Kann,1 and Morten Duno3
1National Eye Clinic, Kennedy Center, Glostrup, Denmark
2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3Department of Clinical Genetics 4062, University Hospital Copenhagen, Copenhagen, Denmark
4Agence National de Recherche sur le Sida (ANRS), Paris, France
5Department of Biomedical Sciences, University of Padua, Padua, Italy
6Centre d’Etude des Transformations des Activite´s Physiques et Sportives (CETAPS), Faculty of Sports Science, University of Rouen,
Rouen, France
Correspondence: Morten Duno, Mo-
lecular Genetics Laboratory, Depart-
ment of Clinical Genetics, University
Hospital Copenhagen, 4062, Bleg-
damsvej 9, DK 2100 Copenhagen,
Denmark;
mdunoe@rh.dk.
Submitted: October 1, 2015
Accepted: December 17, 2015
Citation: Rosenberg T, Nørby S,
Schwartz M, et al. Prevalence and
genetics of Leber hereditary optic
neuropathy in the Danish population.
Invest Ophthalmol Vis Sci.
2016;57:1370–1375. DOI:10.1167/
iovs.15-18306
PURPOSE. In Denmark, the occurrence of Leber hereditary optic neuropathy (LHON) has
continuously been monitored since 1944. We provide here a summary of 70 years of data
collection including registered lines and subjects by the end of 2012.
METHODS. Affected individuals were identified from a national register of hereditary eye
diseases at the National Eye Clinic (NEC), a tertiary low vision rehabilitation center for the
entire Danish population. The assembling of LHON pedigrees was based on the
reconstruction of published families and newly diagnosed cases from 1980 to 2012 identified
in the files of NEC. Genealogic follow-up on the maternal ancestry of all affected individuals
was performed to identify a possible relation to an already known maternal line. A full
genotypic characterization of the nation-based LHON cohort is provided.
RESULTS. Forty different lines were identified. The number of live affected individuals with a
verified mitochondrial DNA mutation was 104 on January 1, 2013, which translates to a
prevalence rate of 1:54,000 in the Danish population.
CONCLUSIONS. Haplogroup distribution as well as mutational spectrum of the Danish LHON
cohort do not deviate from those of other European populations. The genealogic follow-up
reveals a relatively high turnover among families with approximately 15 newly affected
families per century and the dying out of earlier maternal lines.
Keywords: Leber hereditary optic neuropathy, LHON, national cohort study
Leber hereditary optic neuropathy (LHON) is a rare,maternally-inherited dystrophy affecting mainly retinal
ganglion cells and resulting in optic atrophy with subacute
deterioration of central visual function leading to irreversible
blindness in most of the affected.1 Leber hereditary optic
neuropathy is primarily caused by mutations in the mitochon-
drial genome affecting three subunits of respiratory complex I,
nicotinamide adenine dinucleotide hydrogen–ubiquinone oxi-
doreductase, of the oxidative phosphorylation pathway. Three
common mutations, m.3460G>A, m.11778G>A, and
m.14484T>C in MT-ND1, MT-ND4, and MT-ND6, respectively,
are known as the primary pathogenic mutations and account
for approximately 90% of LHON patients of Caucasian origin.2
A novel MT-ND1 mutation, m.3395A>G, associated with the
LHON phenotype has recently been identified in a Danish
patient (Soldath P, written communications, 2015), and in
approximately 1% of the LHON patients other mitochondrial
(mt)DNA variations, primarily affecting the complex I genes,
can be found. However, a stringent pathogenicity of such
variants is often hard to establish.3 In a considerable fraction of
clinically clear-cut patients, no causative mtDNA mutation have
been found; and with an additional pronounced sex-biased
penetrance, the genetic etiology of LHON remains complex.4 It
has been suggested that the specific haplogroup background of
genetically verified LHON patients has an influence on disease
manifestation,5 and several so-called secondary LHON-associat-
ed mtDNA variants have been claimed to play a role in
penetrance and disease expression, though the significance of
such variants still remains uncertain.6
The aim of this study is to present national prevalence data,
genealogic workup, and molecular genetic data on mutations
and haplogroup background of LHON patients in the Danish
population of 5.6 million inhabitants.
MATERIALS AND METHODS
Patients
Patients were recruited from the National Eye Clinic (NEC) for
the Visually Impaired, a tertiary national referral center.
Anamnestic information on hitherto unrecognized family
members was noted and followed by a request of the files
from local eye departments. Supplementary information was
obtained from the Department of Clinical Genetics at the
University Hospital, Rigshospitalet in Copenhagen, which until
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recently was the only center offering genetic analysis for LHON
in Denmark.
The clinical diagnosis was based on a combination of
symptoms and signs; the presence of rapid and painless visual
decline in one eye, mostly to Snellen acuities between 3/60
and 1/60, followed by a similar visual loss in the fellow eye
within days or weeks. Examinations in the acute phase
typically showed swelling of the nerve fibre layer, a circum-
papillary teleangiectic microangiopathy, and large central
scotomas with normal periphery followed by paleness of the
papilla during the following months.
Family history was based on patient interviews and
questionnaires, and affected maternal relatives supported the
clinical diagnosis. Since 1989, mutation analyses have been
performed in at least one member from each line.7 Several
members of a single large multigenerational line (line no. 706)
participated in a research project with the purpose of assessing
heteroplasmy for the pathogenic mutation and the association
between the mutational load and the clinical phenotype.
Prevalence data were calculated based on individuals with
an identified mitochondrial mutation only. Genealogic tracing
along the maternal ancestry line back to at least 1800 was
conducted in every newly identified person manifesting LHON.
Besides the primary mutation, haplogroups and their subclades
were included as a guide for the clarification of the matrilineal
genealogy. Population statistics were obtained through Statis-
tics Denmark (https://www.dst.dk/en, in the public domain).
Molecular Genetics
We isolated DNA from an EDTA blood sample by standard
methods. Since 1989, specific assessment of the three common
LHON mutations, m.3460G>A, m.11778G>A, and
m.14484T>C have been performed by various methods,
ranging from PCR and restriction analysis, over direct
sequencing to allelic discrimination through Taqman assays.
The latter have been performed since 2007. Primers and PCR
conditions are available upon request. All analyses were carried
out in a clinical setting, with informed consent from the
patients. The study adhered to the tenets of the Declaration of
Helsinki.
Comprehensive mtDNA sequencing was performed in eight
individuals by standard next-generation sequencing approach
on PCR products covering the mtDNA sequence,8 using
commercial sequencing technology (IonTorrent; Thermo
Fisher Scientific, Waltham, MA, USA) essentially as described
in Sundaresan et al.9 A mean coverage of >10003 was
achieved.
The haplogroup affiliations10 were based on direct sequenc-
ing of a PCR product covering HVS-1, using forward and
reverse primers spanning m.15714 to 15733 and m.70 to 89,
respectively. We used rCRS/NC_012920 as reference.
The level of heteroplasmy for m.3460G>A in members of
line 706 (the mutational load—i.e., the percentage of mtDNA
harboring the mutation), was determined by solid-phase




By January 1, 2013, 111 persons still living had been diagnosed
with LHON. In seven of these patients, no pathogenic mtDNA
mutation was found. The 104 mutation-positive individuals
correspond to an overall observed prevalence rate of 1:54,000
in the Danish population (Table 1).
The sex proportion was 82 males (1:34,000 male popula-
tion) versus 22 females (1:123,000 female population). For
males, the age at onset was distributed over 6.4 decades with a
median value of 25 years and for females over 4.4 decades with
a median value of 33 years (Fig. 1). Six of 82 males (7.3%) had
disease onset in the first 10 years of life. The age distribution
showed a maximum prevalence for both sexes in the age group
50 to 59 years, except for six males aged 80 years and more
who had a higher age-specific prevalence.
A total of 40 maternal lines were represented in the cohort.
In nine of these, only one live individual was recorded,
additional affected members being deceased. In 15 lines, only
one case of LHON has been detected (Table 2). In the present
cohort, six lines had 6 to 11 affected individuals and nearly half
of the 104 patients belonged to seven of the 40 maternal lines.
In six of the largest genealogies, the eldest obligate carrier was
born before 1850.
Mutations and Haplogroups
Seventy-eight individuals carried the common MT-ND4
m.11778G>A mutation, while 15 and 10 harbored the MT-
ND1 m.3460G>A and MT-ND6 m.14484T>C, respectively. In
one isolated case, a novel MT-ND1 m.3395A>G mutation was
identified. The distribution among the 40 maternal lines
according to mutation was 27 (67%) with MT-ND4 mutation,
7 (18%) with MT-ND6 mutation, 5 (13%) with the classic MT-
ND1 mutation, and 1 with the novel MT-ND1 mutation (Table
TABLE 1. Population Overview and LHON Sex- and Age-Specific Prevalence Rates in the Danish Population of 5.6 Million Inhabitants (January 1,
2013)
Population (P) LHON, n Prevalence, P:N
Age Group, y Males, n Females, n Total, n Males Females Total Males Females Total
0–9 329,266 313,210 642,476 0 0 0 0 0 0
10–19 355,271 338,073 693,344 4 0 4 1:89,000 0 1:173,000
20–29 345,797 336,050 681,847 6 1 7 1:58,000 1:82,000 1:97,000
30–39 350,817 349,217 700,034 2 4 6 1:175,000 1:87,000 1:117,000
40–49 412,036 403,858 815,894 14 4 18 1:29,000 1:101,000 1:45,000
50–59 364,797 362,954 727,751 25 6 31 1:15,000 1:60,000 1:23,000
60–69 341,978 351,538 693,516 17 6 23 1:21,000 1:59,000 1:32,000
70–79 193,604 221,479 415,083 8 1 9 1:24,000 1:221,000 1:46,000
80–89 74,785 117,266 192,051 4 0 4 1:12,000 0 1:48,000
90–99 10,335 29,288 39,623 2 0 2 1:5,000 0 1:20,000
100þ 166 843 1,009 0 0 0 0 0 0
0–100þ 2,778,852 2,823,776 5,602,628 82 22 104 1:34,000 1:123,000 1:54,000
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2). The latter mutation was represented by a single simplex
family. Seven males (from six lines) had a typical clinical course
of LHON, but no mutation was identified in mtDNA in spite of
comprehensive NGS.
The mitochondrial haplogroups represented in the 40 lines
were H (n¼ 14), J (n¼ 8), K (n¼ 6), T (n¼ 7), U (n¼ 4), and
A2 (n¼1). Among the 14 lines belonging to haplogroup H, the
m.11778G>A mutation was present in 11, nine of which were
multigenerationally affected. Only four lines with haplogroup
H represented simplex cases. Sequencing the hypervariable
HVS-1 region allowed classification into subclades, which by
and large confirmed the assignment to separate maternal lines,
and furthermore facilitated the genealogic workup on newly
diagnosed patients (Supplementary Table S1).
The results of the investigation of individuals of line 706,
including the mutational load in the cases of heteroplasmy, are
presented in Figure 2.
DISCUSSION
The present data were collected over a 70-year period,
including the work by Ruth Lundsgaard—whose dissertation
on Leber’s disease appeared in 194412—and later follow-up by
Seedorff,13 who also added new maternal lines. Since 1980, a
genealogic reconstruction of already known families has been
carried out and together with newly diagnosed cases,
integrated in a running and currently updated register of
hereditary eye conditions in Denmark. The data set is
characterized by a high degree of completeness regarding
affected individuals and their pathogenic mutation(s), which
until recently is mainly is ascribed to a centralized care for
visually impaired people in Denmark.
Limitations
Prior to the introduction of molecular genetic verification, an
LHON diagnosis was solely based on family history and clinical
criteria. Pertinent genealogic studies sometimes were able to
document ancestral relations to a maternal LHON carrier
generations back without any known disease manifestation in
the intervening period. Thus, genealogy was an important part
of the diagnostic process. Optic neuropathy is a common cause
of visual impairment among patients referred to NEC. In most
instances, however, extensive neurologic assessment was
carried out before referral, excluding a primary disease.
Historically, LHON has been confused with dominant optic
atrophy, which is prevalent in Denmark. Patients with LHON
have also been wrongly diagnosed as suffering from toxic
amblyopia, tobacco–alcohol amblyopia, or optic neuritis. It
was important for a reliable clinical diagnosis of LHON that
patients were examined from early visual loss to late stage.
Since the pioneering work by Ruth Lundsgaard in the 1940s,
the studies by Tove Seedorff during the 1960s, and the
renewed attention from the 1980s and onward, there has been
an awareness of LHON among Danish ophthalmologists.
Combined with a relatively easy access to ophthalmologic
service in this country, we have been able to go through the
results of the clinical examinations from the early phase in all
patients. Mutation analyses were performed in all patients and
supported the diagnosis in 104 of 111 subjects. The remaining
seven subjects were not included in the study. In conclusion,
we consider the risk of the inclusion of false positive LHON
cases as minimal. During the last 20 years, mtDNA mutation
analysis is performed in otherwise unexplained cases of optic
neuropathy. This has increased the fraction of solitary LHON
cases including patients, which otherwise would have escaped
recognition. However, it is likely that some cases were
overlooked due to unawareness, atypical clinical course,
erroneous diagnosis, or because of missing referral or reporting
to our clinic. This implies that the prevalence calculations may
be considered as minimum figures.
Prevalence
Lundsgaard’s original data set comprised 101 familial cases
distributed among 20 families and five clinically well-docu-
mented solitary cases, which translates to a prevalence of
1:37,000 based on the size of the Danish population in 1944
(Statistics Denmark). The updated 2013 data set approximates
a considerably lower prevalence of 1:54,000. In the same
period, the overall size of the Danish population rose from 4 to
5.6 million inhabitants. The number of affected individuals in
the Danish population, however, was strikingly similar (106 in
1944 vs. 104 in 2013). Earlier, a familial occurrence was an
important diagnostic criterion and Lundsgaard demanded a
minimum of two affected members to define a LHON family.
For practical reasons we considered also isolated cases where
genealogic research failed to establish any connection to other
cases. To a large degree, the genealogic conclusions were
corroborated by haplotype analyses. In Lundsgaard’s terms, our
40 maternal lines consist of 25 familial cases and 15 isolated
cases. A closer look at the pedigrees shows a quite high
turnover among families with approximately 15 newly affected
families per century and the dying out of earlier maternal lines.
Live affected descendants or known mutation carriers were
present in only nine of the families described by Lundsgaard.
The introduction of mutation screening in cases of optic
neuropathies without known etiology has led to a genetic
diagnosis in many simplex cases, which were missed before
the mutational era. The latter factor explains the rise in the
number of isolated cases. The increase in the number of
immigrants, in whom genealogic tracking down along the
female line was not possible, may have contributed to an
overestimation of this number.
The number of epidemiologic studies in LHON is still
limited. A Finnish study showed a nearly identical number of
affected in a population size comparable to the Danish.14 In
FIGURE 1. Age at onset among 104 LHON patients with known
mutations. Legend: The age of patients at LHON onset shown as
cumulated numbers (RN) in 5-year intervals. Red bars, males; blue
bars, females. The median age at onset was 25 years in males and 33
years in females.
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contrast, a study from Northeast England found a higher
prevalence of 1:31,000.15 This frequency, however, was based
on the adult population younger than 65 years and conse-
quently not directly comparable with other prevalence data.
Based on an analysis of the families collected by van Senus16 in
The Netherlands, a maximum prevalence, corrected for bias
due to a high fraction of individuals from a m.14484T>C
founder family, reached an estimate of 1:39,000.17 A meta-
analysis of the LHON prevalence in Europe arrived at a
frequency of 1:45,000.18 Thus, the prevalence of affected
LHON patients in different European countries is of the same
magnitude, and geographic differences seem mainly to be due
to different representation of very large pedigrees mimicking
founder effects. In this sense, it is noteworthy that almost half
of the confirmed patients in Denmark represent only 18% of
the maternal lines (7/40). Five of the seven lines stem from
original Lundsgaard families, while a sixth is represented by a
descendant of one of Lundsgaard’s isolated cases.
Several genetic and environmental factors have been
proposed to influence the penetrance of LHON, but the
underlying factors are still poorly understood. Members of
maternal line no. 706 (Fig. 2) strikingly illustrate an association
between mutational load and clinical manifestation. The level
of mutational load in one branch, which did not exhibit LHON,
did not reach above 11%; while in another branch, with several
affected individuals, homoplasmy for the mutation is found. It
is clear, however, that the association is not complete, which is
likely to reflect that the leukocytes of peripheral blood are not
fully representative for the target cells in LHON. A case in
question is the branch marked by an asterisk (Fig. 2): The
individual with a 100% mutational load is clinically unaffected
and has two children with mutational loads below 100%. This
individual is obviously heteroplasmic in the germline and,
since clinically unaffected, is likely also to be heteroplasmic in
the retinal target cells. This figure also illustrates the
reversibility in mutational load within a maternal line.
TABLE 2. Overview of Lines With Known Mutation and Still Alive Affected Members
Line No.







n (M:F) Gene Haplogroup
701 1721 10 49:7 11 (9:2) ND4 K
702 1745 9 15:1 4 (3:1) ND6 J
703 1799 8 23:2 6 ND4 T
706 1842 7 11:5 8 (6:2) ND1 K
707 Unknown 9 15:6 3 (2:1) ND1 T
708 1810 6 3:1 1 ND4 K
710 ~1750 10 14:1 4 ND4 H
711 1773 7 6:2 1 ND4 H
712 1801 8 16:2 5 ND4 H
725 1826 7 11:4 8 (7:1) ND4 J
727 1852 5 13:1 3 (2:1) ND4 H
732 1794 8 12:10 11 (7:4) ND4 H
733 1855 6 6:1 6 (5:1) ND4 H
736 1864 4 7:0 2 ND4 J
737 1877 5 4:0 3 ND4 H
738 ~1870 5 2:0 1 ND4 U
739 1785 7 4:2 1 ND4 T
741 1925 3 1:0 1 ND6 H
742 1956 2 1:0 1 ND4 J
743 1933 3 0:2 1 ND6 H
745 1925 3 0:1 1 ND4 H
746 1928 3 1:0 1 ND6 K
747 1919 3 0:1 1 ND6 T
772 1896 3 2:0 1 ND4 U
773 1913 3 1:1 2 (1:1) ND4 J
774 1921 4 1:0 1 ND4 U
778 1882 6 1:2 1 ND4 U
782 1933 3 1:0 1 ND4 H
792 1852 5 3:0 2 ND4 T
793 1872 5 2:1 1 ND4 H
796 1937 3 1:0 1 ND1 J
797 1874 5 0:2 1 ND4 H
111 1960 2 2:0 2 ND1 K
115 1933 2 1:0 1 ND1 T
138 1934 2 1:0 1 ND4 J
172 Unknown 2 1:0 1 ND6 J
182 1923 2 0:1 1 ND4 T
183 1963 2 0:1 1 ND1* A2a
184 Unknown 2 1:0 1 ND4 K
213 1912 2 1:0 1 ND6 H
* Atypical ND1 mutation.
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Mutational Spectrum
The distribution of the three primary LHON mutations among
the genetically verified patients did not deviate significantly
from previously published distributions in Caucasians,2,15
although the common m.11778G>A is found at a slightly
higher fraction (75% of patients) in the present material. The
most frequent haplogroup among the m.11778G>A lines was
H, which was found in 10 out the the 27 families. The H
haplogroup background has been associated with a reduced
risk of visual failure.5 On the other hand, the J haplogroup
background has been proposed to exacerbate the severity of
both m.11778G>A and m.14484T>C. However, this back-
ground was only observed in 5 of 27 of m.11778G>A families
and two of seven of the m.14484T>C families, indicating that
the J haplogroup does not contribute significantly to the
clinical expression in the Danish population. The patient with
a haplogroup A2 background is of Greenland Inuit descent and
belongs to the common Inuit subhaplogroup A2a.19 The
overall haplogroup distribution of the remaining 39 LHON
lines shows no striking deviation from the haplogroup
distribution in the general Danish population or in Europe as
a whole.20 At present, it seems justified to conclude that we
still do not have reliable prediction tools for the risk of disease
manifestation in genetic counseling.
In seven patients with a clear-cut LHON phenotype, we
were unable to identify any mtDNA alteration. This is not
uncommon. Achilli and colleagues3 sequenced the entire
mtDNA of 174 patients highly suspected for LHON, but
harboring none of the three common mutations, and only
detected 16 with a possibly pathogenic mtDNA mutation.
In our search for a genetic basis of newly diagnosed cases of
LHON, we have so far focused solely on mutations in mtDNA,
and especially in the genes encoding subunits of complex I
harboring the three primary LHON mutations worldwide.
However, since the majority of complex I subunits (38 out of
45) are encoded by the nuclear genome, the existence of
nuclear LHON mutations seems likely. In fact, for years
Lundsgaard’s family U, consisting of two affected brothers,
has appealed to us as a possible candidate family for Mendelian
inheritance of LHON and lately this hunch has been
substantiated by a male-to-male transmission in the following
generation of an otherwise unaffected pedigree. Current
methods for genome sequencing have finally made it possible
to pursue the search for nuclear mutations causing Leber
hereditary optic neuropathy.
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